Summary of Study ST003536
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002176. The data can be accessed directly via it's Project DOI: 10.21228/M8BV78 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003536 |
| Study Title | Probiotics and their metabolite spermidine enhance IFN-γ+CD4+ T cell immunity to inhibit hepatitis B virus |
| Study Summary | The therapeutic potential of commensal microbes and their metabolites is promising in the functional cure of chronic hepatitis B virus (HBV) infection, which is defined as HBsAg loss. Here, using both specific-pathogen-free and germ-free mice, we report that probiotics significantly promote the decline of HBsAg and inhibit HBV replication by enhancing intestinal homeostasis and provoking intrahepatic IFN-γ+CD4+ T cell immune response. Depletion of CD4+ T cells or blockage of IFN-γ abolishes probiotics-mediated HBV inhibition. Specifically, probiotics-derived spermidine accumulates in gut and transports to liver, where it exhibits a similar anti-HBV effect. Mechanistically, spermidine enhances IFN-γ+CD4+ T cell immunity by autophagy. Strikingly, administration of probiotics in HBV patients reveals a preliminary trend to accelerate the decline of serum HBsAg. In conclusion, probiotics and theirs derived spermidine promote HBV clearance via autophagy-enhanced IFN-γ+CD4+ T cell immunity, highlighting the therapeutic potential of probiotics and spermidine for the functional cure of HBV patients. |
| Institute | Shandong University |
| Last Name | Wang |
| First Name | Tixiao |
| Address | 44 Wenhua Xi Road, Jinan, Shandong |
| tixwang@163.com | |
| Phone | 18560082747 |
| Submit Date | 2024-10-10 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | cdf |
| Analysis Type Detail | LC-MS |
| Release Date | 2024-11-15 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002176 |
| Project DOI: | doi: 10.21228/M8BV78 |
| Project Title: | Metabolomics data of feces from Control and BLE mice |
| Project Summary: | Untargeted metabolomic analysis showed that 38 metabolites were significantly different between control and BLE mice. Among them, oligosaccharides (1-kestose, raffinose, maltotriose), amino acids (N-Acetyl-L-leucine, glutamic acid) and polyamine (spermidine, SPD) were the most varied enriched metabolites. |
| Institute: | Shandong University |
| Last Name: | Wang |
| First Name: | Tixiao |
| Address: | 44# Wenhua Xi Road, Jinan, Shandong Province, 250012, China |
| Email: | tixwang@163.com |
| Phone: | 18560082747 |
Subject:
| Subject ID: | SU003665 |
| Subject Type: | Other organism |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Gender: | Male |
Factors:
Subject type: Other organism; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Sample source | Treatment |
|---|---|---|---|
| SA387535 | B2 | Feces | BLE |
| SA387536 | B10 | Feces | BLE |
| SA387537 | B9 | Feces | BLE |
| SA387538 | B8 | Feces | BLE |
| SA387539 | B7 | Feces | BLE |
| SA387540 | B6 | Feces | BLE |
| SA387541 | B5 | Feces | BLE |
| SA387542 | B4 | Feces | BLE |
| SA387543 | B1 | Feces | BLE |
| SA387544 | C3 | Feces | Control |
| SA387545 | C10 | Feces | Control |
| SA387546 | C9 | Feces | Control |
| SA387547 | C8 | Feces | Control |
| SA387548 | C7 | Feces | Control |
| SA387549 | C6 | Feces | Control |
| SA387550 | C5 | Feces | Control |
| SA387551 | C4 | Feces | Control |
| SA387552 | C2 | Feces | Control |
| Showing results 1 to 18 of 18 |
Collection:
| Collection ID: | CO003658 |
| Collection Summary: | Male five-week-old C57BL/6J mice were hydrodynamically injected with 6 μg of AAV/HBV1.2 plasmid and gavage fed with probiotics (BLE, PBS as control) daily starting at 3 day post of hydrodynamically injection. Feces collected from Control and BLE mice after 6 weeks. |
| Sample Type: | Feces |
Treatment:
| Treatment ID: | TR003674 |
| Treatment Summary: | Male five-week-old C57BL/6J mice were hydrodynamically injected with 6 μg of AAV/HBV1.2 plasmid and gavage fed with probiotics (BLEl) daily at 3 dpi of hydrodynamically injection. |
Sample Preparation:
| Sampleprep ID: | SP003672 |
| Sampleprep Summary: | Take 50±1mg sample into the 2mL EP tubes, extracted with 0.3mL extraction liquid (VMethanol: VChlorofrom = 3:1), add 20μL of L-2-Chlorophenylalanine (1mg/mL stock in dH2O) as internal standard, vortex mixing for 30s; Homogenized in ball mill for 4min at 45Hz, then ultrasound treated for 5min (incubated in ice water); Centrifuge for 15min at 12000rpm, 4℃; Transfer the supernatant (0.2mL) into a fresh 2mL GC/MS glass vial , take 30μL from each sample and pooling as QC sample. Dry completely in a vacuum concentrator without heating; Add 30μL Methoxy amination hydrochloride (20mg/mL in pyridine) incubated for 30min at 80℃; Add 40μL of the BSTFA regent (1% TMCS, v/v) to the sample aliquots, incubated for 1.5h at 70℃; Add 5μL FAMEs (Standard mixture of fatty acid methyl esters, C8-C16:1mg/mL; C18-C24:0.5mg/mL in chloroform) to the QC sample when cooling to the room temperature; All samples were analyzed by gas chromatograph system coupled with a Pegasus HT time-of-flight mass spectrometer (GC-TOF-MS). |
Combined analysis:
| Analysis ID | AN005808 |
|---|---|
| Analysis type | MS |
| Chromatography type | GC |
| Chromatography system | Agilent 7890B |
| Column | Agilent DB5-MS (30m x 0.25mm, 0.25um) |
| MS Type | ESI |
| MS instrument type | GC-TOF |
| MS instrument name | Agilent 7890B |
| Ion Mode | UNSPECIFIED |
| Units | peak area |
Chromatography:
| Chromatography ID: | CH004411 |
| Chromatography Summary: | GC-TOF-MS analysis was performed using an Agilent 7890 gas chromatograph system coupled with a Pegasus HT time-of-flight mass spectrometer. The system utilized a DB-5MS capillary column coated with 5% diphenyl cross-linked with 95% dimethylpolysiloxane (30m×250μm inner diameter, 0.25μm film thickness; J&W Scientific, Folsom, CA, USA). A 1μL aliquot of the analyte was injected in splitless mode. Helium was used as the carrier gas, the front inlet purge flow was 3mL min−1, and the gas flow rate through the column was 1mL min−1. The initial temperature was kept at 50°C for 1min, then raised to 310°C at a rate of 10°C min−1, then kept for 8min at 310°C. The injection, transfer line, and ion source temperatures were 280, 280, and 250°C, respectively. The energy was -70eV in electron impact mode. The mass spectrometry data were acquired in full-scan mode with the m/z range of 50-500 at a rate of 20 spectra per second after a solvent delay of 6.27min. |
| Instrument Name: | Agilent 7890B |
| Column Name: | Agilent DB5-MS (30m x 0.25mm, 0.25um) |
| Column Temperature: | 50°C |
| Flow Gradient: | - |
| Flow Rate: | - |
| Solvent A: | - |
| Solvent B: | - |
| Chromatography Type: | GC |
MS:
| MS ID: | MS005528 |
| Analysis ID: | AN005808 |
| Instrument Name: | Agilent 7890B |
| Instrument Type: | GC-TOF |
| MS Type: | ESI |
| MS Comments: | Chroma TOF 4.3X software of LECO Corporation and LECO-Fiehn Rtx5 database were used for raw peaks exacting, the data baselines filtering and calibration of the baseline, peak alignment, deconvolution analysis, peak identification and integration of the peak area1. Both of mass spectrum match and retention index match were considered in metabolites identification. Remove peaks detected in <50% of QC samples or RSD＞30% in QC samples. |
| Ion Mode: | UNSPECIFIED |
